Healthcare Dive published a current U.S. medical or healthcare update on November 9, 2026. The story is receiving priority because the agent rated it as a timely, high-impact topic in drugs, treatments and FDA action. This article summarizes the verified source material and separates confirmed facts from issues that still need to be watched.
What happened?
CMS is postponing the end of Medicare payments for third-party remote patient monitoring services until 2029, but virtual care stakeholders maintain that these payments are needed to operate RPM programs that expand access to care.
Key facts from the source
- So, in the proposed 2027 Medicare Physician Fee Schedule, CMS said that Medicare would only pay for RPM services provided by clinical staff employed by the practice where the patient is receiving care.
- Share Copy link Email LinkedIn X/Twitter Facebook Print The CMS is delaying an unpopular proposal that ends Medicare payment for remote patient monitoring services provided by third-party vendors that contract with healthcare providers.
- Similarly, Brian Scarpelli, executive director of the Connected Health Initiative, said in a statement, "CHI will push CMS on clinical staffing arrangements for remote monitoring before the 2029 deadline." In addition to delaying the third-party RPM payments proposal, the CMS finalized other changes to RPM reimbursement, including only paying for remote monitoring of non-physiologic metrics, such as medication adherence and pain levels, for established patients and not new ones.
- The proposal was meant to take effect at the beginning of 2027, but in the final rule, CMS deferred the start date to the beginning of 2029.
- This ability to intervene quickly has been credited with improving outcomes, reducing hospitalizations and readmissions and supporting chronic disease management.
Why this matters in U.S. healthcare
FDA actions involving drugs, biologics, therapies, or safety warnings can influence treatment options, prescribing information, access, monitoring, and manufacturer responsibilities.
Who may be affected?
Patients, prescribers, pharmacists, hospitals, health plans, manufacturers, and specialty practices may be affected depending on the product and indication.
What to watch next
- Read the FDA announcement and product labeling or safety communication.
- Watch for indication, eligibility, safety, supply, or access details.
- Look for payer and clinical-guideline updates after the federal action.
- Do not treat a news summary as prescribing guidance.
Key takeaway
This is a developing medical-news item selected for recency, U.S. relevance, potential impact, source quality, and independent coverage where available. The original source remains the authority for exact clinical, regulatory, safety, coverage, or policy details.
Frequently asked questions
Is this article medical advice?
No. It is a news summary based on cited public sources and is not a substitute for clinical guidance or patient-specific medical advice.
How current is this story?
The agent prioritizes articles published within its configured hot-news window and rejects older stories from automatic publication.
How is a topic selected?
Stories are ranked using freshness, U.S. relevance, potential healthcare impact, source authority, and corroboration across separate sources.
Sources
Primary source: CMS postpones RPM payment halt for 2 years — Healthcare Dive.